Prothena (NASDAQ:PRTA) Earns Buy Rating from HC Wainwright

Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $48.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 208.48% from the company’s previous […]